Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Summary
Third Opinion Trial Synopsis:
This study is exploring two drugs called Teclistamab and Lenalidomide + Dexamethasone to see which one works better at fighting cancer in people with high-risk smoldering multiple myeloma. Smoldering multiple myeloma is a condition where someone has a higher risk of developing cancer, but no symptoms. The goal is to find a treatment for this condition as there are currently no approved therapies available.
This study is exploring two drugs called Teclistamab and Lenalidomide + Dexamethasone to see which one works better at fighting cancer in people with high-risk smoldering multiple myeloma. Smoldering multiple myeloma is a condition where someone has a higher risk of developing cancer, but no symptoms. The goal is to find a treatment for this condition as there are currently no approved therapies available.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: Teclistamab Lenalidomide (also called Revlimid) Dexamethasone (also called Decadron)
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: Teclistamab Lenalidomide (also called Revlimid) Dexamethasone (also called Decadron)
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: